Brought to you by 
Lavipharm / Zonagen merger terminated
28 Mar 2003
Executive Summary
Under a definitive agreement for a tax-free stock swap, Lavipharm Corp. (Lavipharm Group's worldwide headquarters outside of Greece; drug formulation and delivery technologies) plans to go public through a reverse acquisition that will merge it into the public company Zonagen Inc. (reproductive health).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com